Our research encompasses a dynamic process that moves from bedside to bench and back again. We utilize information obtained from clinical cancer cohorts to deepen our understanding of the cell biology principles that underpin the heterogeneity and mechanisms of human cancer. Concurrently, the results from our studies are translated back to the bedside, where theories and findings from preclinical experiments inform the design of investigator-initiated clinical trials for patients affected by the disease. Our ultimate goal is to identify druggable key molecular pathways that target specific genomic abnormalities, ultimately aiming to attenuate cancer cell growth, reduce disease burden, increase quality of life, and improve patient survival.